Demonstrates improved hyperthermia outcomes in bladder cancer using antibody-conjugated nanoparticles, suggesting a novel therapeutic approach.
Our αPD-L1@MCL enables hyperthermia with magnetic nanoparticles and immunotherapy with an anti-PD-L1 antibody. These findings support further development of hyperthermia mediated by anti-PD-L1 antibody-conjugated magnetic nanoparticles as a promising therapeutic strategy for BC.
No takes yet. Share an insight, caveat, or question.
Gonda et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: